Shuangjiang Li1, Zhang Yang2, Heng Du3, Wenbiao Zhang1, Guowei Che1, Lunxu Liu1. 1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. 2. Division of General Thoracic Surgery, Bern University Hospital, University of Bern, Bern, Switzerland. 3. Division of Pulmonary Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Our propensity score-matching (PSM) study evaluated the prognostic significance of systemic inflammation response index (SIRI) for patients undergoing video-assisted thoracoscopic surgery lobectomy for non-small-cell lung cancer (NSCLC). METHODS: This study was conducted on prospectively maintained database in our institution between December 2013 and March 2015. Pre-operative SIRI was calculated by peripheral monocyte × neutrophil/lymphocyte counts. Survival analysis was performed to distinguish differences in post-operative survival between patients stratified by an optimum cut-off of SIRI. Multivariable Cox proportional hazards regression models were established to determine independent prognostic factors. RESULTS: There were 390 patients with resected NSCLC included. A SIRI of 0.99 was identified as the optimum cut-off regarding to post-operative survival. Both overall survival (OS) and disease-free survival (DFS) in patients with SIRI >0.99 were significantly shortened than those in patient with SIRI ≤0.99. Patients with SIRI >0.99 had significantly lower rates of OS and DFS compared to those patients with SIRI ≤0.99. These differences still remained significant after subgroup analyses and PSM analyses. Multivariable analyses on the entire cohort and the PSM cohort commonly demonstrated that high pre-operative SIRI could be an independent prognostic factor for unfavourable OS and DFS of NSCLC. CONCLUSIONS: SIRI serves as a novel risk stratification tool to refine prognostic prediction for surgically resected NSCLC. SIRI may help surgeons to screen high-surgical-risk patients and formulate individualized treatment schemes.
BACKGROUND: Our propensity score-matching (PSM) study evaluated the prognostic significance of systemic inflammation response index (SIRI) for patients undergoing video-assisted thoracoscopic surgery lobectomy for non-small-cell lung cancer (NSCLC). METHODS: This study was conducted on prospectively maintained database in our institution between December 2013 and March 2015. Pre-operative SIRI was calculated by peripheral monocyte × neutrophil/lymphocyte counts. Survival analysis was performed to distinguish differences in post-operative survival between patients stratified by an optimum cut-off of SIRI. Multivariable Cox proportional hazards regression models were established to determine independent prognostic factors. RESULTS: There were 390 patients with resected NSCLC included. A SIRI of 0.99 was identified as the optimum cut-off regarding to post-operative survival. Both overall survival (OS) and disease-free survival (DFS) in patients with SIRI >0.99 were significantly shortened than those in patient with SIRI ≤0.99. Patients with SIRI >0.99 had significantly lower rates of OS and DFS compared to those patients with SIRI ≤0.99. These differences still remained significant after subgroup analyses and PSM analyses. Multivariable analyses on the entire cohort and the PSM cohort commonly demonstrated that high pre-operative SIRI could be an independent prognostic factor for unfavourable OS and DFS of NSCLC. CONCLUSIONS: SIRI serves as a novel risk stratification tool to refine prognostic prediction for surgically resected NSCLC. SIRI may help surgeons to screen high-surgical-risk patients and formulate individualized treatment schemes.
Authors: Giorgio Carlo Ginesu; Panagiotis Paliogiannis; Claudio F Feo; Maria Laura Cossu; Antonio Mario Scanu; Alessandro Fancellu; Alessandro Giuseppe Fois; Angelo Zinellu; Teresa Perra; Simone Veneroni; Alberto Porcu Journal: Curr Oncol Date: 2022-05-08 Impact factor: 3.109
Authors: Mengliu Zhu; Li Chen; Xiangyi Kong; Xiangyu Wang; Xingrui Li; Yi Fang; Jing Wang Journal: Cancer Manag Res Date: 2022-02-25 Impact factor: 3.989